Cancer-associated fibroblasts at the unfavorable desmoplastic stroma promote colorectal cancer aggressiveness: Potential role of ADAM9.
ADAM9
a disintegrin and metalloproteinases
cancer-associated fibroblasts
colorectal cancer
desmoplastic reaction
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
15 05 2022
15 05 2022
Historique:
revised:
10
12
2021
received:
15
05
2021
accepted:
04
01
2022
pubmed:
27
1
2022
medline:
29
4
2022
entrez:
26
1
2022
Statut:
ppublish
Résumé
The tumor microenvironment plays a key role in cancer aggressiveness. Desmoplastic reaction (DR), morphologically classified as Mature, Intermediate and Immature types, has previously been shown to be highly prognostic in colorectal cancer (CRC) and it consists to a large extent of cancer-associated fibroblasts (CAFs). The aim of our study was to characterize the molecular background of DR and understand the effects of CAFs in tumor aggressiveness. The prognostic significance of DR was initially examined in 1497 patients. Then CAFs originating from patient tissues with different DR types were isolated and their impact on tumor growth was examined both in vitro and in vivo. DR was shown to be highly prognostic, with patients within the Immature DR group conferring the worst relapse-free survival. The conditioned media of CAFs from tumor with Immature-type DR (CAFs
Substances chimiques
Membrane Proteins
0
ADAM Proteins
EC 3.4.24.-
ADAM9 protein, human
EC 3.4.24.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1706-1721Informations de copyright
© 2022 UICC.
Références
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.
McAllister SS, Weinberg RA. Tumor-host interactions: a far-reaching relationship. J Clin Oncol. 2010;28:4022-4028.
Ueno H, Jones A, Jass JR, Talbot IC. Clinicopathological significance of the “keloid-like” collagen and myxoid stroma in advanced rectal cancer. Histopathology. 2002;40:327-334.
Ueno H, Jones AM, Wilkinson KH, Jass JR, Talbot IC. Histological categorisation of fibrotic cancer stroma in advanced rectal cancer. Gut. 2004;53:581-586.
Ueno H, Kanemitsu Y, Sekine S, et al. A multicenter study of the prognostic value of desmoplastic reaction categorization in stage II colorectal cancer. Am J Surg Pathol. 2019;43:1015-1022.
Ueno H, Kanemitsu Y, Sekine S, et al. Desmoplastic pattern at the tumor front defines poor-prognosis subtypes of colorectal cancer. Am J Surg Pathol. 2017;41:1506-1512.
Ueno H, Konishi T, Ishikawa Y, et al. Histologic categorization of fibrotic cancer stroma in the primary tumor is an independent prognostic index in resectable colorectal liver metastasis. Am J Surg Pathol. 2014;38:1380-1386.
Ueno H, Sekine S, Oshiro T, et al. Disentangling the prognostic heterogeneity of stage III colorectal cancer through histologic stromal categorization. Surgery. 2018;163:777-783.
Ueno H, Shinto E, Kajiwara Y, et al. Prognostic impact of histological categorisation of epithelial-mesenchymal transition in colorectal cancer. Br J Cancer. 2014;111:2082-2090.
Nearchou IP, Kajiwara Y, Mochizuki S, Harrison DJ, Caie PD, Ueno H. Novel internationally verified method reports desmoplastic reaction as the most significant prognostic feature for disease-specific survival in stage II colorectal cancer. Am J Surg Pathol. 2019;43:1239-1248.
Ueno H, Ishiguro M, Nakatani E, et al. Prognostic value of desmoplastic reaction characterisation in stage II colon cancer: prospective validation in a phase 3 study (SACURA trial). Br J Cancer. 2021;124:1088-1097. doi:10.1038/s41416-020-01222-8
Sueyama T, Kajiwara Y, Mochizuki S, et al. Periostin as a key molecule defining desmoplastic environment in colorectal cancer. Virchows Arch. 2021;478:865-874.
Ueno H, Shinto E, Shimazaki H, et al. Histologic categorization of desmoplastic reaction: its relevance to the colorectal cancer microenvironment and prognosis. Ann Surg Oncol. 2015;22:1504-1512.
Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009;9:239-252.
Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloproteinases. Mol Aspects Med. 2008;29:258-289.
Mochizuki S, Okada Y. ADAMs in cancer cell proliferation and progression. Cancer Sci. 2007;98:621-628.
Murphy G. Regulation of the proteolytic disintegrin metalloproteinases, the “Sheddases”. Semin Cell Dev Biol. 2009;20:138-145.
Carl-McGrath S, Lendeckel U, Ebert M, Roessner A, Röcken C. The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer. Int J Oncol. 2005;26:17-24.
Gavert N, Conacci-Sorrell M, Gast D, et al. L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J Cell Biol. 2005;168:633-642.
Grützmann R, Lüttges J, Sipos B, et al. ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma. Br J Cancer. 2004;90:1053-1058.
O'Shea C, McKie N, Buggy Y, et al. Expression of ADAM-9 mRNA and protein in human breast cancer. Int J Cancer. 2003;105:754-761.
Roemer A, Schwettmann L, Jung M, et al. Increased mRNA expression of ADAMs in renal cell carcinoma and their association with clinical outcome. Oncol Rep. 2004;11:529-536.
Shintani Y, Higashiyama S, Ohta M, et al. Overexpression of ADAM9 in non-small cell lung cancer correlates with brain metastasis. Cancer Res. 2004;64:4190-4196.
Zigrino P, Mauch C, Fox JW, Nischt R. Adam-9 expression and regulation in human skin melanoma and melanoma cell lines. Int J Cancer. 2005;116(116):853-859.
Mazzocca A, Coppari R, De Franco R, et al. A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal interactions. Cancer Res. 2005;65:4728-4738.
Amin MBES, Greene FL, Byrd DR, et al. In: Gress DM, Meyer LR, eds. AJCC Cancer Staging Manual. 8th ed. Switzerland: Springer; 2017:251-274.
Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-174.
Hotoda N, Koike H, Sasagawa N, Ishiura S. A secreted form of human ADAM9 has an alpha-secretase activity for APP. Biochem Biophys Res Commun. 2002;293:800-805.
Mochizuki S, Ao T, Sugiura T, et al. Expression and function of a disintegrin and metalloproteinases in cancer-associated fibroblasts of colorectal cancer. Digestion. 2020;101:18-24.
Sato T, Vries RG, Snippert HJ, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature. 2009;459:262-265.
Mitsui Y, Mochizuki S, Kodama T, et al. ADAM28 is overexpressed in human breast carcinomas: implications for carcinoma cell proliferation through cleavage of insulin-like growth factor binding protein-3. Cancer Res. 2006;66:9913-9920.
Mochizuki S, Soejima K, Shimoda M, et al. Effect of ADAM28 on carcinoma cell metastasis by cleavage of von Willebrand factor. J Natl Cancer Inst. 2012;104:906-922.
Rueden CT, Schindelin J, Hiner MC, et al. ImageJ2: ImageJ for the next generation of scientific image data. BMC Bioinform. 2017;18:529.
Wright CL, Stewart ID. Histopathology and mismatch repair status of 458 consecutive colorectal carcinomas. Am J Surg Pathol. 2003;27:1393-1406.
Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6:392-401.
McDonald LT, LaRue AC. Hematopoietic stem cell derived carcinoma-associated fibroblasts: a novel origin. Int J Clin Exp Pathol. 2012;5:863-873.
Ostman A, Augsten M. Cancer-associated fibroblasts and tumor growth-bystanders turning into key players. Curr Opin Genet Dev. 2009;19:67-73.
Pietras K, Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res. 2010;316:1324-1331.
Mongaret C, Alexandre J, Thomas-Schoemann A, et al. Tumor invasion induced by oxidative stress is dependent on membrane ADAM 9 protein and its secreted form. Int J Cancer. 2011;129:791-798.
Shigemura K, Sung SY, Kubo H, et al. Reactive oxygen species mediate androgen receptor- and serum starvation-elicited downstream signaling of ADAM9 expression in human prostate cancer cells. Prostate. 2007;67:722-731.
Sung SY, Kubo H, Shigemura K, et al. Oxidative stress induces ADAM9 protein expression in human prostate cancer cells. Cancer Res. 2006;66:9519-9526.
Izumi Y, Hirata M, Hasuwa H, et al. A metalloprotease-disintegrin, MDC9/meltrin-gamma/ADAM9 and PKCdelta are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor. EMBO J. 1998;17:7260-7272.
Fry JL, Toker A. Secreted and membrane-bound isoforms of protease ADAM9 have opposing effects on breast cancer cell migration. Cancer Res. 2010;70:8187-8198.
Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol. 2004;5:816-826.
Ao T, Kajiwara Y, Yonemura K, et al. Prognostic significance of histological categorization of desmoplastic reaction in colorectal liver metastases. Virchows Arch. 2019;475:341-348.
Ao T, Kajiwara Y, Yonemura K, et al. Morphological consistency of desmoplastic reactions between the primary colorectal cancer lesion and associated metastatic lesions. Virchows Arch. 2020;477:47-55.
Cao L, Sun PL, He Y, Yao M, Gao H. Desmoplastic reaction and tumor budding in cervical squamous cell carcinoma are prognostic factors for distant metastasis: a retrospective study. Cancer Manag Res. 2020;12:137-144.
Hernandez-Ruiz E, Hernandez-Munoz I, Masferrer E, et al. A myxoid fibrotic reaction pattern is associated with metastatic risk in cutaneous squamous cell carcinoma. Acta Derm Venereol. 2019;99:89-94.
Zhai Q, Fan J, Lin Q, et al. Tumor stromal type is associated with stromal PD-L1 expression and predicts outcomes in breast cancer. PLoS One. 2019;14:e0223325.
Stuart Hicks DL, Sinkevicius K, Scribner J, et al. IMGC936, a first-in-class ADAM9-targeting antibody-drug conjugate, demonstrates promising anti-tumor activity. Cancer Res. 2019;79:1533.